75722 Federal Register / Vol. 65, No. 233 / Monday, December 4, 2000 / Notices

guidance). There will be no special

considerations.

(4) on page 42225, the grant category

beginning in the second column under

the heading ‘‘Healthy Start Initiative

Eliminating Disparities in Perinatal

Health Border Health (CFDA

#93.926N)’’, is amended to: (a) further

restrict eligibility to applicants who will

establish community-based consortia of

individuals and organizations

(including State Title V agencies,

consumers of project services, public

health departments, hospitals,

community health centers, and other

significant sources of health care

services) that are appropriate for

participation. Eligibility remains open

to any public or private entity,

including an Indian tribe or tribal

organization (as defined at 25 U.S.C.

450b)); (b) restrict project areas to those

which target a geographic area with high

annual rates of infant mortality within

62 miles from the Mexican border in a

particular State, i.e., no statewide

programs will be funded; and (c) require

that grantees coordinate their services

and activities with State Title V

agencies. Funding priorities and/or

preferences will be given only to

applicants who were recipients of

Healthy Start community-based grants

awarded prior to July 2000 (details will

be provided in the application

guidance). There will be no special

considerations. The estimated amount

of this competition will be up to

$1,500,000. It is anticipated that two

awards will be made.

The amendments above conform to

changes made in the Healthy Start

program by Title XV of Public Law 106–

310. Prospective applicants who have

submitted letters of intent or requested

application materials have been notified

directly of this withdrawal. It is

anticipated that applications for all four

of these competitions will be available

December 21, 2000. The deadline for

Letters of Intent will be January 15,

2001. The application deadline is March

1, 2001. The anticipated project award

date is June 1, 2001.

Two pre-application conferences are

scheduled for these competitions. The

first conference will be held on the

afternoon of Wednesday, December 13,

2000, from 1:30–4:00 p.m., at the Hyatt

Regency Washington on Capitol Hill,

400 New Jersey Avenue, NW,

Washington, DC, 20001, (202)737–1234.

The second conference will be held on

Friday, December 15, 2000, at the Hyatt

Regency Dallas at Reunion, 300 Reunion

Blvd., Dallas, TX, 75207–4498,

(214)651–1234, Fax: (214)742–8126,

Website: www.hyatt.com. If you plan to

attend either one of these preapplication conferences, please call

Shirletia Meredith at (301)443–0543.

FOR FURTHER INFORMATION CONTACT:

Angela Hayes Toliver or Beverly Wright

at 301–443–0543 (for CFDA #93.926E);

Madelyn Renteria or Alexandra Cossi, at

301–443–0543 (for CFDA #93.926K);

Janice Berger or John McGovern at, 301–

443–8427(for CFDA #93.926L); or David

de la Cruz, at 301–443–8427 (for CFDA

#93.926N), Division of Perinatal

Systems and Women’s Health, Maternal

and Child Health Bureau, Health

Resources and Services Administration,

Room 11A–05, Parklawn Building, 5600

Fishers Lane, Rockville, MD 20857;

telephone 1–301–443–8427.

Dated: November 29, 2000.

Claude Earl Fox,

Administrator.

[FR Doc. 00–30824 Filed 12–1–00; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

Availability of Funds Announced in the

HRSA Preview; Withdrawal

AGENCY: Health Resources and Services

Administration.

ACTION: Notice; withdrawal.

SUMMARY: In the Federal Register issue

of Friday, July 7, 2000, in Part III

‘‘Availability of Funds Announced in

the HRSA Preview’’ of FR Doc. 00–

16874, on page 42219, the grant category

beginning in the second column under

the heading ‘‘Continuing Education and

Development Cooperative Agreement to

Advance Education and Program/Policy

Development in Maternal and Child

Health (CFDA #93.110TP),’’ is

withdrawn from competition while the

Agency is considering its options

regarding the activities proposed for

support. After a decision is made,

another announcement will be

published in the Federal Register.

Prospective applicants who have

submitted letters of intent or requested

application materials from the HRSA

Grants Application Center have been

notified directly of this withdrawal.

FOR FURTHER INFORMATION CONTACT:

Carol Galaty or Sharon Adamo, Office of

Program Development, Maternal and

Child Health Bureau, Health Resources

and Services Administration, Room

11A–22, Parklawn Building, 5600

Fishers Lane, Rockville, MD 20857;

telephone 1–301–443–2778.

Dated: November 29, 2000.

Claude Earl Fox,

Administrator.

[FR Doc. 00–30825 Filed 12–1–00; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

Availability of Funds Announced in the

HRSA Preview; Withdrawal

AGENCY: Health Resources and Services

Administration.

ACTION: Notice; withdrawal.

SUMMARY: In the Federal Register notice

of Friday, July 7, 2000, in Part III

‘‘Availability of Funds Announced in

the HRSA Preview’’ of FR Doc. 00–

16874, on page 42223, the grant category

beginning in the second column under

the heading ‘‘The Perinatal Systems and

Women’s Health National Resource

Center (CFDA #93.926D),’’ is withdrawn

from competition while the Agency is

considering its options regarding the

activities proposed for support. After a

decision is made, another

announcement will be published in the

Federal Register.

Prospective applicants who have

submitted letters of intent or requested

application materials from the HRSA

Grants Application Center have been

notified directly of this withdrawal.

FOR FURTHER INFORMATION CONTACT:

Beverly Wright, Division of Perinatal

Systems and Women’s Health, Maternal

and Child Health Bureau, Health

Resources and Services Administration,

Room 11A–05, Parklawn Building, 5600

Fishers Lane, Rockville, MD 20857;

telephone 1–301–443–8427.

Dated: November 29, 2000.

Claude Earl Fox,

Administrator.

[FR Doc. 00–30826 Filed 12–1–00; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment

Request, The Cardiovascular Health

Study (CHS)

AGENCY: In compliance with the

requirement of section 3506(c)(2)(A) of

the Paperwork Reduction Act of 1995,

for opportunity for public comment on

proposed data collection projects, the

National Heart, Lung, and Blood

Federal Register / Vol. 65, No. 233 / Monday, December 4, 2000 / Notices 75723

Institute (NHLBI), the National

Institutes of Health (NIH) will publish

periodic summaries of proposed

projects to be submitted to the Office of

Management and Budget (OMB) for

review and approval.

Proposed Collection

Title: The Cardiovascular Health

Study. Type of Information Request:

Revision. (OMB No. 0925–0334). Need

and Use of Information Collection: This

study will quantify associations

between conventional and hypothetical

risk factors and coronary heart disease

(CHD) and stroke in people age 65 years

and older. The primary objectives

include quantifying associations of risk

factors with subclinical disease,

characterize the natural history of CHD,

stroke and identify factors associated

with clinical course. The findings will

provide important information on

cardiovascular disease in an older U.S.

population and lead to early treatment

of risk factors associated with disease

and identification of factors which may

be important in disease prevention.

Frequency of Response: twice a year

(participants) or once per cardiovascular

disease event (proxies and physicians);

Affected Public: Individuals. Types of

Respondents: Individuals recruited for

CHS and their selected proxies and

physicians. The annual reporting

burden is as follows: Estimated Number

of Respondents: 4,606; Estimated

Number of Responses per respondent:

4.55; and Estimated Total Annual

Burden Hours Requested: 1,719.

There are no capital, operating, or

maintenance costs to report.

Type of respondents

Estimated

number of

respondents

Estimated

number of responses per

respondent*

Average burden

hours per

response

Estimated total

annual burden

hours

requested

Participants .................................................................................................. 3,580 5.6 0.25 1,665

Physicians .................................................................................................... 606 1.0 0.10 20

Participant proxies ....................................................................................... 420 1.0 0.25 35

Total .................................................................................................. 4,606 4.55 0.246 1,719

*Total for 3 years.

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed collection of information will

have practical utility; (2) The accuracy

of the agency’s estimate of burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used; (3)

Ways to enhance the quality, utility, and

clarity of the information to be

collected; and (4) Ways to minimize the

burden of collection of information on

those who are to respond, including the

use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To

request more information on the

proposed project or to obtain a copy of

data collection plans and instruments,

contact Dr. Diane Bild, Division of

Epidemiology and Clinical

Applications, Epidemiology and

Biometry Program, NHLBI, NIH, II

Rockledge Centre, 6701 Rockledge

Drive, MSC 7934, Bethesda, MD 20892–

7934, or call non-toll-free number (301)

435–0707, or e-mail your request,

including your address to: bild@nih.gov.

DATES: Comments Due Date: Comments

regarding this information collection are

best assured of having their full effect if

received on or before February 2, 2001.

Dated: November 16, 2000.

Peter Savage,

Acting Director, Division of Epidemiology and

Clinical Applications, National Heart, Lung,

and Blood Institute.

[FR Doc. 00–30713 Filed 12–1–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

NAG–1: A Non-Steroidal AntiInflammatory Drug Related Gene

Which Has Anti-Tumorigenic

Properties

Thomas E. Eling, Seung Joon Baek

(NIEHS)

DHHS Reference No. E–170–00/0 filed

08 Sep 2000

Licensing Contact: Richard Rodriguez;

301/496–7056 ext. 287; e-mail:

rodrigur@od.nih.gov

Non-steroidal anti-inflammatory

drugs (NSAIDs) are widely used in the

treatment of inflammatory disease, and

their anti-inflammatory effects are

believed to result from their ability to

inhibit the formation of prostaglandins

by prostaglandin H synthase (COX).

Two forms of prostaglandin H have been

identified, COX–1 and COX–2. The

former seems to be constitutively

expressed in a variety of tissues while

the high expression of the latter has

been reported in colorectal tumors.

NSAIDs have been shown to be effective

in reducing human colorectal cancers

and possibly breast and lung cancers.

While the exact mechanism(s) by which

NSAIDs function has not been

elucidated, they could potentially play

a critical role in detecting, diagnosing

and treating inflammatory diseases as

well as cancer. The present invention

relates to screening methods for the

identification of agonistic and/or

antagonistic agents for the activation of

the promoter region of NAG–1.

Additional claims are directed to 1) the